Verano Holdings (VRNO) Non Operating Income (2021 - 2026)
Verano Holdings' (VRNO) quarterly Non Operating Income came in at -$12.3 million in Q1 2026, down 34.29% year-on-year from -$18.7 million in Q1 2025, and down 29.0% on a QoQ basis from -$9.5 million in Q4 2025.
Verano Holdings (VRNO) Non Operating Income (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Non Operating Income data on file, last reported at -$12.3 million in Q1 2026.
- On a quarterly basis, Non Operating Income fell 34.29% year-over-year to -$12.3 million in Q1 2026; TTM through Mar 2026 was -$60.7 million, a 21.7% decrease from a year earlier, with the FY2025 full-year figure at -$53.6 million, up 2.14% from the prior year.
- Non Operating Income for Q1 2026 stood at -$12.3 million, down from -$9.5 million in the prior quarter.
- Over the last five years, Non Operating Income for VRNO reached as high as $3.5 million in Q2 2022 and fell as low as -$24.7 million in Q3 2025.
- Historically, Non Operating Income has averaged -$12.8 million across 5 years, with a median of -$13.9 million in 2024.
- Across the five-year window, Non Operating Income soared 159.19% in 2022 and tumbled 545.66% in 2023, its largest moves.
- Year by year, Non Operating Income stood at -$15.3 million in 2022, then increased by 22.46% to -$11.9 million in 2023, then fell by 6.18% to -$12.6 million in 2024, then increased by 24.48% to -$9.5 million in 2025, then dropped by 29.0% to -$12.3 million in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were -$12.3 million in Q1 2026, -$9.5 million in Q4 2025, and -$24.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | -12.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.31 Mn |
| Dec 31, 2025 | -9.54 Mn |
| Sep 30, 2025 | -24.67 Mn |
| Jun 30, 2025 | -14.21 Mn |
| Mar 31, 2025 | -9.17 Mn |
| Dec 31, 2024 | -12.64 Mn |
| Sep 30, 2024 | -13.86 Mn |
| Jun 30, 2024 | -14.24 Mn |
| Mar 31, 2024 | -15.11 Mn |
| Dec 31, 2023 | -11.90 Mn |
| Sep 30, 2023 | -15.17 Mn |
| Jun 30, 2023 | -15.81 Mn |
| Mar 31, 2023 | -15.91 Mn |
| Dec 31, 2022 | -15.35 Mn |
| Sep 30, 2022 | -10.69 Mn |
| Jun 30, 2022 | 3.55 Mn |
| Mar 31, 2022 | -10.67 Mn |
| Dec 31, 2021 | -7.75 Mn |
| Sep 30, 2021 | -8.11 Mn |
| Jun 30, 2021 | -5.99 Mn |